Molecular data
| Molecular formula | Mixture (GHK-Cu + TB-500 + BPC-157 + KPV) |
|---|---|
| Sequence | Components: GHK-Cu (Gly-His-Lys + Cu2+); TB-500 (Ac-LKKTETQ); BPC-157 (GEPPPGKPADDAGLV); KPV (Lys-Pro-Val) |
| Physical form | Lyophilized powder |
| Available sizes | 80mg |
How it works
Growth-Factor & Angiogenic Signalling
In preclinical research, BPC-157 is studied in skin, tendon, muscle and bone models through growth-factor upregulation and angiogenic signalling. TB-500 (a thymosin β-4 fragment) is studied for cell migration and fibrotic endpoints across several animal models.
- BPC-157: growth-factor upregulation and angiogenesis in animal models
- TB-500: actin-binding, with cell migration measured in culture
- Both studied across tendon, muscle, cardiac and dermal injury models
Extracellular Matrix & Collagen
GHK-Cu is a copper-binding tripeptide. Collagen and elastin synthesis, endothelial activity and fibroblast migration have been measured in cell culture following exposure, which is why it is a common reference compound in extracellular-matrix research.
- Collagen and elastin synthesis studied in fibroblast models
- Endothelial and fibroblast activity measured in culture
- Studied in extracellular-matrix and dermal models
Inflammation Modulation
KPV is the C-terminal tripeptide of α-MSH. In vitro work reports reduced NF-κB and MAP-kinase signalling at nanomolar concentrations, with correspondingly lower cytokine output in the same assays.
- Reduced NF-κB and MAP-kinase signalling reported in vitro
- Lower TNF-α, IL-6 and IL-1β measured in research models
- Adds a cytokine-signalling component to the blend
What the research shows
Tendon, Muscle & Connective Tissue
BPC-157 and structurally related peptides are studied in preclinical tendon, muscle and bone models. Human data remains limited.
Cell Migration & Angiogenesis
BPC-157, TB-500 and GHK-Cu are frequently used together in in-vitro and ex-vivo systems to probe endothelial activity and matrix gene expression.
Skin, Collagen & Wound Models
GHK-Cu is a reference compound for collagen and elastin synthesis in fibroblast culture; the blend is studied in dermal models.
Peptide Class Pharmacology
This peptide class is characterised by its signalling mechanisms; the human evidence base remains limited for all four components.
Specification
| Product Type | Four-peptide research blend |
|---|---|
| Component 1 | GHK-Cu 50 mg — copper-binding tripeptide |
| Component 2 | TB-500 10 mg — thymosin β-4 fragment |
| Component 3 | BPC-157 10 mg — gastric pentadecapeptide |
| Component 4 | KPV 10 mg — α-MSH C-terminal tripeptide |
| Total Peptide Content | 80 mg per vial |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| COA | Included with every order |
Frequently asked questions
What is the KLOW blend?
KLOW is a four-peptide research blend combining GHK-Cu (50 mg), TB-500 (10 mg), BPC-157 (10 mg) and KPV (10 mg) — 80 mg of total peptide per vial. It groups short peptides that are individually studied in matrix, cell-migration and cytokine-signalling research.
What is each peptide in KLOW characterised for?
BPC-157 is studied in tendon, muscle and bone models via growth-factor signalling; TB-500 (a thymosin β-4 fragment) in cell-migration and fibrosis models; GHK-Cu in collagen-synthesis and fibroblast models; KPV in NF-κB signalling models. The four span growth-factor, angiogenic, matrix and cytokine pathways.
Why combine these four peptides?
Each component acts through a different mechanism. Combining them gives a single preparation that engages several pathways at once — angiogenic and growth-factor signalling (BPC-157, TB-500), extracellular matrix (GHK-Cu), and cytokine signalling (KPV) — which is why blends are used to compare multi-pathway against single-compound conditions.
Is KLOW FDA approved?
No. None of the four components is an FDA-approved drug. BPC-157 specifically is not approved by the FDA or EMA, and a 2023 FDA Category 2 designation restricts injectable compounding in the United States. Research-grade KLOW is supplied strictly for in vitro laboratory research.
What research contexts use these peptides?
BPC-157, TB-500 and GHK-Cu are used in in-vitro systems, ex-vivo tissue explants and animal models, with endpoints such as endothelial-cell activity in angiogenesis assays, fibroblast matrix gene expression, cell migration and wound closure. KPV is used in inflammatory-signalling research. There is no human data for this blend.
How should the KLOW blend be stored?
Lyophilized KLOW should be stored at -20°C, protected from light and moisture, to preserve the integrity of all four peptides.
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.